Ravuconazole

Ravuconazole (formerly BMS-207147 and ER-30346) is a triazole structurally related to fluconazole and voriconazole. It is being developed by Bristol-Myers Squibb for oral use. Its trade name has not been announced.

As with all azole antifungal agents, ravuconazole works principally by inhibition of cytochrome P450 14a-demethylase (P45014DM). This enzyme is in the sterol biosynthesis pathway that leads from lanosterol to ergosterol. The potency of ravuconazole to inhibit sterol C14 demethylation is similar to that of itraconazole.

Usual Doses
No data are available from Phase I and ongoing Phase II clinical trials. Typical doses are not yet known.

Side-Effects
Results of the clinical trials in men have not yet been reported.
No side effects have been noted in rats and dogs who have been treated with ravuconazole for a week .